# Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

> **NCT04034485** · PHASE3 · COMPLETED · sponsor: **LIB Therapeutics LLC** · enrollment: 65 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** lerodalcibep
- **DRUG:** evolocumab

## Key facts

- **NCT ID:** NCT04034485
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-07
- **Primary completion:** 2022-09-12
- **Final completion:** 2023-01-30
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034485, "Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04034485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*